Karthikesh Omkaram, Ramprasad Reddy A, E. Galeti, Surender Reddy, M. Aleem, Gousia Begum S
This is the first time a large endovesical leiomyoma of the urinary bladder has been reported in India. A 44-year-old woman had painless gross haematuria, increased urine frequency, an incomplete emptying feeling, and left loin discomfort. Imaging and cystoscopy revealed a 6 x 5 cm projecting endovesical tumour emerging from the bladder's base near the left vesico-ureteric junction. Transurethral bladder resection with few biopsies was performed, histopathological examination revealed a pathological diagnosis of a leiomyoma of the urinary bladder. Intravesical complete excision of the tumor was performed after ligating its pedicle. Complete surgical resection is a very effective treatment, associated with almost no recurrence. We discuss the relevant recent literature of bladder leiomyoma.
这是印度首次报道膀胱内大型平滑肌瘤。一位44岁的女性出现无痛性血尿、尿频增加、排空不完全和左腰部不适。影像学和膀胱镜检查显示，左侧膀胱-输尿管交界处附近的膀胱底部出现一个6 x 5厘米的膀胱内肿瘤。进行了经尿道膀胱切除术，但很少进行活检，组织病理学检查显示病理诊断为膀胱平滑肌瘤。结扎肿瘤蒂后进行膀胱内完全切除。完全手术切除是一种非常有效的治疗方法，几乎不会复发。我们讨论了最近有关膀胱平滑肌瘤的文献。
{"title":"Urinary Bladder Leiomyoma Causing Obstructive Uropathy: A Case Report and Literature Review","authors":"Karthikesh Omkaram, Ramprasad Reddy A, E. Galeti, Surender Reddy, M. Aleem, Gousia Begum S","doi":"10.32948/auo.2023.01.24","DOIUrl":"https://doi.org/10.32948/auo.2023.01.24","url":null,"abstract":"This is the first time a large endovesical leiomyoma of the urinary bladder has been reported in India. A 44-year-old woman had painless gross haematuria, increased urine frequency, an incomplete emptying feeling, and left loin discomfort. Imaging and cystoscopy revealed a 6 x 5 cm projecting endovesical tumour emerging from the bladder's base near the left vesico-ureteric junction. Transurethral bladder resection with few biopsies was performed, histopathological examination revealed a pathological diagnosis of a leiomyoma of the urinary bladder. Intravesical complete excision of the tumor was performed after ligating its pedicle. Complete surgical resection is a very effective treatment, associated with almost no recurrence. We discuss the relevant recent literature of bladder leiomyoma.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47381699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sunil V. Jagtap, Shubham S. Jagtap, Kaushiki Varshney, Y. Jadhav, P. Shah
Renal leiomyosarcoma is an extremely rare malignant tumor. On clinical presentation and radio imaging it is challenging to make an accurate preoperative diagnosis. In our case, a 59-year-old female presented with history of left-sided flank pain, intermittent hematuria and weight loss of 6 months duration. She was known case of hypertension and diabetes mellitus of 20 years and on regular treatment. On the abdomino-pelvis sonography showed an exophytic cortical mass lesion measuring 4.0 x 3.8 cm lesion. Magnetic resonance imaging abdomen and pelvis (plain) shows a well defined non encapsulated exophytic predominantly solid mass lesion measuring 4.3 x 4 x 4.5 cm is noted in the anterior cortex of left kidney at interpolar region. There was no evidence of any regionalor distant metastesis. Patient underwent left radical nephrectomy. On histopathology reported as renal leiomyosarcoma. Immuhistochemistry showed smooth muscle actin diffusely and desmin focally positive. We present this review of rare case of primary renal leiomyosarcoma for its clinical presentation, radiographic findings, and pathologic features.
摘要肾脏平滑肌肉瘤是一种极为罕见的恶性肿瘤。在临床表现和放射影像学上，对其进行准确的术前诊断具有挑战性。在我们的病例中，一名59岁的女性表现为左侧腰痛，间歇性血尿和体重下降，持续6个月。她是已知的高血压和糖尿病病例，20年，定期治疗。腹部-骨盆超声显示外生性皮质肿块，大小为4.0 x 3.8 cm。腹部和骨盆的磁共振成像(平片)显示左肾前皮质极间区有一个轮廓清晰的非包膜外生实性肿块，大小为4.3 x 4 x 4.5 cm。没有任何区域或远处转移的证据。病人接受左肾根治性切除术。组织病理学报告为肾平滑肌肉瘤。免疫组化示平滑肌肌动蛋白弥漫性阳性，desmin局部阳性。我们在此回顾罕见的原发性肾脏平滑肌肉瘤的临床表现、影像学表现和病理特征。
{"title":"Primary Renal Leiomyosarcoma: Case Report and Review of the Literature","authors":"Sunil V. Jagtap, Shubham S. Jagtap, Kaushiki Varshney, Y. Jadhav, P. Shah","doi":"10.32948/auo.2023.01.28","DOIUrl":"https://doi.org/10.32948/auo.2023.01.28","url":null,"abstract":"Renal leiomyosarcoma is an extremely rare malignant tumor. On clinical presentation and radio imaging it is challenging to make an accurate preoperative diagnosis. In our case, a 59-year-old female presented with history of left-sided flank pain, intermittent hematuria and weight loss of 6 months duration. She was known case of hypertension and diabetes mellitus of 20 years and on regular treatment. On the abdomino-pelvis sonography showed an exophytic cortical mass lesion measuring 4.0 x 3.8 cm lesion. Magnetic resonance imaging abdomen and pelvis (plain) shows a well defined non encapsulated exophytic predominantly solid mass lesion measuring 4.3 x 4 x 4.5 cm is noted in the anterior cortex of left kidney at interpolar region. There was no evidence of any regionalor distant metastesis. Patient underwent left radical nephrectomy. On histopathology reported as renal leiomyosarcoma. Immuhistochemistry showed smooth muscle actin diffusely and desmin focally positive. We present this review of rare case of primary renal leiomyosarcoma for its clinical presentation, radiographic findings, and pathologic features.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47555586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cade C. Lewis, Aidan J. Heslin, Cole R. Formslag, Mark R. Wakefield, Yujiang Fang
This is a letter to the editor on the discussion on COVID-19 and prostate cancer.
这是一封关于讨论COVID-19和前列腺癌的致编辑的信。
{"title":"COVID-19 and Prostate Cancer, Can Two Negatives Equal a Positive?","authors":"Cade C. Lewis, Aidan J. Heslin, Cole R. Formslag, Mark R. Wakefield, Yujiang Fang","doi":"10.32948/auo.2023.01.01","DOIUrl":"https://doi.org/10.32948/auo.2023.01.01","url":null,"abstract":"This is a letter to the editor on the discussion on COVID-19 and prostate cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44751719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kevin Z. Qi, Miriam P. Palomino, Justin D. Murray, Madeline N. Agee, M. Wakefield, Yujiang Fang
This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer.
这是一封关于COVID-19疫苗与膀胱癌讨论的致编辑的信。
{"title":"COVID-19 Vaccine and Bladder Cancer: Friend or Foe?","authors":"Kevin Z. Qi, Miriam P. Palomino, Justin D. Murray, Madeline N. Agee, M. Wakefield, Yujiang Fang","doi":"10.32948/auo.2022.12.30","DOIUrl":"https://doi.org/10.32948/auo.2022.12.30","url":null,"abstract":"This is a letter to the editor on the discussion on COVID-19 vaccine and bladder cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45460696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy besides androgen deprivation therapy. Varied newer drugs and combinations in recent years have improved the outcome of prostate cancer in terms of both overall survival(OS) and metastases free survival(MFS). Some of the latest drugs which have cleared regulatory approval are Abiraterone, Enzalutamide,Apulatamide, Sipuleucel-T etc. However still more needs to be explored to negate and overcome the resistant mechanisms. Here in this article we have summarized the varied newer and recent developments in advanced prostate cancer.
{"title":"Recent Advances in Advance Prostate Cancer","authors":"Nishant Lohia","doi":"10.32948/auo.2022.12.29","DOIUrl":"https://doi.org/10.32948/auo.2022.12.29","url":null,"abstract":"Prostate cancer being the second most frequent and fifth leading cause of mortality has led to conduct of many new clinical trials and development of newer therapeutic agents. In the last decade with better understanding of biology of disease there is dramatic improvement and sea change in survival outcomes in advanced prostate cancer with advent of chemotherapy, targeted therapy immunotherapy besides androgen deprivation therapy. Varied newer drugs and combinations in recent years have improved the outcome of prostate cancer in terms of both overall survival(OS) and metastases free survival(MFS). Some of the latest drugs which have cleared regulatory approval are Abiraterone, Enzalutamide,Apulatamide, Sipuleucel-T etc. However still more needs to be explored to negate and overcome the resistant mechanisms. Here in this article we have summarized the varied newer and recent developments in advanced prostate cancer.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47106106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pseudoepitheliomatous hyperplasia (PEH) is a benign condition marked by reactive epithelial proliferation seen in response to various insults like trauma, infection, persistent inflammation and neoplasia. In this report, we discuss a case of a 35-year-old man who presented with a perineal swelling, later turned into a non-healing ulcer, first diagnosed as PEH. Still, after clinical suspicion, a deeper biopsy was conducted, confirming the diagnosis of squamous cell carcinoma and directing treatment appropriately. Non-healing perineal lesions are not uncommon. Most of the lesions turn out to be Squamous Cell Carcinoma. But, if the histopathological picture suggests Pseudoepitheliomatous Hyperplasia, it is vital to consider the limitations of the biopsy, and a solid clinicopathological correlation is required to look aggressively for underlying Squamous Cell Carcinoma. Due to the benign nature of PEH, most cases are treated via excision biopsy, while grafts or flaps are occasionally required to restore severe tissue defects. It is therefore crucial to rule out and distinguish this condition from other benign and malignant conditions, as the treatment and prognosis differ widely. It is of utmost importance to sample the base of the lesion, analyze multiple sections, and consider clinical data to ensure an accurate diagnosis.
{"title":"Pseudoepitheliomatous Hyperplasia: Harbinger of Underlying Squamous Cell Carcinoma - Lessons Learnt","authors":"S. Krishnamoorthy, H. Sekar, L. Joseph, J. Kumar","doi":"10.32948/auo.2022.12.22","DOIUrl":"https://doi.org/10.32948/auo.2022.12.22","url":null,"abstract":"Pseudoepitheliomatous hyperplasia (PEH) is a benign condition marked by reactive epithelial proliferation seen in response to various insults like trauma, infection, persistent inflammation and neoplasia. In this report, we discuss a case of a 35-year-old man who presented with a perineal swelling, later turned into a non-healing ulcer, first diagnosed as PEH. Still, after clinical suspicion, a deeper biopsy was conducted, confirming the diagnosis of squamous cell carcinoma and directing treatment appropriately.\u0000Non-healing perineal lesions are not uncommon. Most of the lesions turn out to be Squamous Cell Carcinoma. But, if the histopathological picture suggests Pseudoepitheliomatous Hyperplasia, it is vital to consider the limitations of the biopsy, and a solid clinicopathological correlation is required to look aggressively for underlying Squamous Cell Carcinoma. Due to the benign nature of PEH, most cases are treated via excision biopsy, while grafts or flaps are occasionally required to restore severe tissue defects.\u0000It is therefore crucial to rule out and distinguish this condition from other benign and malignant conditions, as the treatment and prognosis differ widely. It is of utmost importance to sample the base of the lesion, analyze multiple sections, and consider clinical data to ensure an accurate diagnosis.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43391710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The "immune checkpoint" of T cells has attracted much attention in tumor immunotherapy. It is widely accepted that suppressor T cell immune checkpoints promote tumor immune escape through negative immune regulatory signals (cytotoxic T lymphocyte associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, among others). The current data suggest that the PD-1 and CTLA-4 receptors inhibit the T cell receptor and its proliferation. Blockade of the PD-I/PD-L1 and/or CTLA-4/CD 28 pathways has shown favorable tumor outcomes in clinical trials in advance-stage renal cancer. This article reviews the role of CTLA-4/CD 28 pathway in renal cell carcinoma. Here we discuss the basics of the CTLA-4 pathway from a physiological perspective and evaluate the results of clinical studies of CTLA-4 alone and in combination with PD-1/PD-L1 blockers to support future studies of combination immunotherapy.
{"title":"Targeting CTLA-4 in Cancer: Biological Insights with a Focus on Renal Cell Carcinoma","authors":"Juan Wu, Yang Ren, Jun Xie, Dong-sheng Li","doi":"10.32948/auo.2022.12.15","DOIUrl":"https://doi.org/10.32948/auo.2022.12.15","url":null,"abstract":"Renal cell carcinoma (RCC) is a complex group of malignant tumors characterized by immunosuppression and high invasiveness. In the majority of patients with advanced renal cell carcinoma, treatment fails to achieve a complete cure post-treatment. Efforts are needed to develop new therapeutics to improve the outcome of renal cell carcinoma. The \"immune checkpoint\" of T cells has attracted much attention in tumor immunotherapy. It is widely accepted that suppressor T cell immune checkpoints promote tumor immune escape through negative immune regulatory signals (cytotoxic T lymphocyte associated antigen 4 [CTLA-4], programmed cell death 1 [PD-1], B7-H3, and B7-H4, among others). The current data suggest that the PD-1 and CTLA-4 receptors inhibit the T cell receptor and its proliferation. Blockade of the PD-I/PD-L1 and/or CTLA-4/CD 28 pathways has shown favorable tumor outcomes in clinical trials in advance-stage renal cancer. This article reviews the role of CTLA-4/CD 28 pathway in renal cell carcinoma. Here we discuss the basics of the CTLA-4 pathway from a physiological perspective and evaluate the results of clinical studies of CTLA-4 alone and in combination with PD-1/PD-L1 blockers to support future studies of combination immunotherapy.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43891157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent studies revealed the involvement of ferroptosis metabolism, lipid peroxidation, and System XC-GSH-GPX4 shafts as major mechanisms closely related to RCC progression. Nanoparticles in combination with small molecular ferroptosis induction agents have the advantages of solubility, targeted enhancement, low systemic toxicity, controllable drug control, and synergy advantage in emerging combination therapies. In the future, it is possible to be used in nano treatment. The relationship between ferroptosis-related mechanisms and RCC progression and its role in the treatment could provide novel treatment strategies for patients with advance-stage RCC.
{"title":"Research Progress on Ferroptosis as a Therapeutic Strategy in Renal Cell Carcinoma","authors":"Liu Minna, Min Bai, N. Cui, Yi Ding, Peng Zhang","doi":"10.32948/auo.2022.12.09","DOIUrl":"https://doi.org/10.32948/auo.2022.12.09","url":null,"abstract":"Renal cell carcinoma (RCC) is a common type of kidney cancer in adults and constitutes approximately 90% of all renal malignancies. Although advancements have been made in the treatment of RCC, the 5 -year survival rate is still low, and new treatment modalities are still required. Ferroptosis is an iron-dependent programmed cell death caused by the accumulation of lipid peroxide products. Recent studies revealed the involvement of ferroptosis metabolism, lipid peroxidation, and System XC-GSH-GPX4 shafts as major mechanisms closely related to RCC progression. Nanoparticles in combination with small molecular ferroptosis induction agents have the advantages of solubility, targeted enhancement, low systemic toxicity, controllable drug control, and synergy advantage in emerging combination therapies. In the future, it is possible to be used in nano treatment. The relationship between ferroptosis-related mechanisms and RCC progression and its role in the treatment could provide novel treatment strategies for patients with advance-stage RCC.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49379444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hezhen Chu, Kongdong Li, Jie Gu, Wen-chao Xie, Yimin Xie, Jun Ma
Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1) with the characterization in prostate cancer patients, and detected the roles of INE1 in cell autophagy and apoptosis in prostate cancer cells. Our results showed that the lncRNA INE1 expression highly correlate with patients’ survival times, tumor stage, biochemical recurrence, disease recurrence and Gleason pattern. High expression of INE1 was detected in prostate cancer cells, and knockdown INE1 by siRNA resulted in significant inhibition of cell viability. In addition, silencing INE1 induced early autophagy and pro-apoptosis, which augments cisplatin (CDDP)-induced cell apoptosis. Moreover, INE1 played an anti-apoptotic role by targeting the serine/arginine-rich splicing factor 2 (SRSF2).
{"title":"Long Non-coding RNA INE1 Induced Autophagy Promotes Sensitivity of Prostate Cancer Cells to Cisplatin","authors":"Hezhen Chu, Kongdong Li, Jie Gu, Wen-chao Xie, Yimin Xie, Jun Ma","doi":"10.32948/auo.2022.11.24","DOIUrl":"https://doi.org/10.32948/auo.2022.11.24","url":null,"abstract":"Prostate cancer is most prevalent malignancy of males in the world. In recent years, long non-coding RNAs (lncRNAs) were identified, and their functions are associated with prostate cancer initiation and progression. However, their molecular mechanisms still need to be elucidated before the clinical utility. In the present study, we identified the correlation of lncRNA inactivation escape 1 (INE1) with the characterization in prostate cancer patients, and detected the roles of INE1 in cell autophagy and apoptosis in prostate cancer cells. Our results showed that the lncRNA INE1 expression highly correlate with patients’ survival times, tumor stage, biochemical recurrence, disease recurrence and Gleason pattern. High expression of INE1 was detected in prostate cancer cells, and knockdown INE1 by siRNA resulted in significant inhibition of cell viability. In addition, silencing INE1 induced early autophagy and pro-apoptosis, which augments cisplatin (CDDP)-induced cell apoptosis. Moreover, INE1 played an anti-apoptotic role by targeting the serine/arginine-rich splicing factor 2 (SRSF2).","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41586571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan
Purpose To identify the role of long non-coding RNA FAM66C in the metastatic progression of prostate cancer cells and its underlying mechanisms. Methods The Cancer Genome Atlas (TCGA) data was utilized to determine the relative expression of lncRNA FAM66C in prostate cancer patients with lymph node metastasis. Knockdown FAM66C by siRNA was performed to investigate the effects of FAM66C in cell migration and epithelial-mesenchymal transition (EMT) by wound healing assay and Western blotting. The proteasome inhibitor MG132 and lysosomal inhibitor chloroquine (CQ) were used to determine the effect of these pathways in FAM66C-regulated cell migration. The c-jun-N-Terminal Kinase (JNK) inhibitor SP600125 was used to identify the role of JNK signaling in FAM66C-regulated cell migration and the proteasome and lysosome pathways. Results A lower expression of lncRNA FAM66C was noted in the most prostate cancer patients. Knockdown of FAM66C in human prostate cancer DU145 and PC-3 cells promoted EMT and cell migration, which was suppressed by proteasomal inhibitor MG132 and lysosomal inhibitor CQ. Knockdown of FAM66C induced JNK signaling, cell migration and invasion, and activation of proteasome and lysosome pathways were suppressed by JNK inhibitor SP600125. Conclusion This study provided new evidence of the role of lncRNA FAM66C in the regulation of JNK signaling mediated proteasome and lysosome pathways affecting migration ability of prostate cancer cells.
{"title":"Long Non-Coding RNA FAM66C Promotes Prostate Cancer Metastasis via JNK-Mediated Proteasome and Lysosomal Pathway","authors":"Zhenqian Qin, Kongdong Li, Jie Gu, Yimin Xie, Xuefeng Yuan","doi":"10.32948/auo.2022.11.23","DOIUrl":"https://doi.org/10.32948/auo.2022.11.23","url":null,"abstract":"Purpose To identify the role of long non-coding RNA FAM66C in the metastatic progression of prostate cancer cells and its underlying mechanisms.\u0000Methods The Cancer Genome Atlas (TCGA) data was utilized to determine the relative expression of lncRNA FAM66C in prostate cancer patients with lymph node metastasis. Knockdown FAM66C by siRNA was performed to investigate the effects of FAM66C in cell migration and epithelial-mesenchymal transition (EMT) by wound healing assay and Western blotting. The proteasome inhibitor MG132 and lysosomal inhibitor chloroquine (CQ) were used to determine the effect of these pathways in FAM66C-regulated cell migration. The c-jun-N-Terminal Kinase (JNK) inhibitor SP600125 was used to identify the role of JNK signaling in FAM66C-regulated cell migration and the proteasome and lysosome pathways.\u0000Results A lower expression of lncRNA FAM66C was noted in the most prostate cancer patients. Knockdown of FAM66C in human prostate cancer DU145 and PC-3 cells promoted EMT and cell migration, which was suppressed by proteasomal inhibitor MG132 and lysosomal inhibitor CQ. Knockdown of FAM66C induced JNK signaling, cell migration and invasion, and activation of proteasome and lysosome pathways were suppressed by JNK inhibitor SP600125.\u0000Conclusion This study provided new evidence of the role of lncRNA FAM66C in the regulation of JNK signaling mediated proteasome and lysosome pathways affecting migration ability of prostate cancer cells.","PeriodicalId":33190,"journal":{"name":"Annals of Urologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42672162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：